OPEN END TURBO LONG - ORION B | Market Closed - Börse Stuttgart 15:24:49 2024-05-28 EDT | ||
| 1.2 EUR | -5.51% |
|
| Current month | +9.09% | ||
| 1 month | +10.09% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ORION OYJ
Latest news about ORION OYJ
More news
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 1.2 | -5.51% |
| 24-05-27 | 1.27 | +2.42% |
| 24-05-24 | 1.24 | -1.59% |
| 24-05-23 | 1.26 | +0.80% |
| 24-05-22 | 1.25 | +0.81% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 03:24 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ORION OYJ |
| Issuer | Morgan Stanley |
| WKN | ME9QY0 |
| ISIN | DE000ME9QY05 |
| Date issued | 2024-03-06 |
| Strike | 24.92 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.32 € |
|---|---|
| Lowest since issue | 0.75 € |
Company Profile
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
-
Consensus: Orion Oyj
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.01
EUR
Average target price
39
EUR
Spread / Average Target
+5.38%
- Stock Market
- Certificates
- Certificat
